In vivo molecular imaging of HER2 expression in a rat model of Barrett's esophagus adenocarcinoma

Diseases of the Esophagus

Volumn 28, Issue 4, 2015, Pages 394-403

  Realdon, S ^a,b   Dassie, E ^a,b   Fassan, M ^c   Dall'Olmo, L ^a   Hatem, G ^c   Buda, A ^c   Arcidiacono, D ^a,b   Diamantis, G ^a   Zhang, H ^d   Greene, M I ^d   Sturniolo, G C ^c   Rugge, M ^c   Alberti, A ^b,c   Battaglia, G ^a,c  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Barrett's esophagus; Confocal laser endomicroscopy; Esophageal adenocarcinoma; Human epidermal growth factor receptor 2; Molecular imaging

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN KINASE B; TRAMADOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BARRETT ESOPHAGUS; CANCER DIAGNOSIS; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; ENDOTRACHEAL INTUBATION; ENZYME PHOSPHORYLATION; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOJEJUNOSTOMY; FEASIBILITY STUDY; FIBEROSCOPE; IMMUNOFLUORESCENCE; IN VIVO STUDY; MOLECULAR IMAGING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ADENOCARCINOMA; ANIMAL; BIOPSY; CHEMICALLY INDUCED; COMPLICATION; CONFOCAL MICROSCOPY; DISEASE MODEL; ENDOSCOPY; ESOPHAGUS TUMOR; FLUORESCENT ANTIBODY TECHNIQUE; INTRAVITAL MICROSCOPY; METABOLISM; PROCEDURES; SPRAGUE DAWLEY RAT; SQUAMOUS CELL CARCINOMA; STAINING;

ADENOCARCINOMA; ANIMALS; BARRETT ESOPHAGUS; BIOPSY; CARCINOMA, SQUAMOUS CELL; DISEASE MODELS, ANIMAL; ENDOSCOPY; ESOPHAGEAL NEOPLASMS; FLUORESCENT ANTIBODY TECHNIQUE; INTRAVITAL MICROSCOPY; MICROSCOPY, CONFOCAL; MOLECULAR IMAGING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ERBB-2; STAINING AND LABELING;

EID: 84928584792     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/dote.12210     Document Type: Article

References (40)

1. Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Bhardwaj A, McGarrity T J, Stairs D B, Mani H. Barrett's esophagus: emerging knowledge and management strategies. Patholog Res Int 2012; 2012: 814146.
3. Bhat S, Coleman H G, Yousef F etal. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J Natl Cancer Inst 2011; 103: 1049-1057.
4. Thrift A P, Pandeya N, Whiteman D C. Current status and future perspectives on the etiology of esophageal adenocarcinoma. Front Oncol 2012; 2: 11.
5. Wang K K, Sampliner R E. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008; 103: 788-797.
6. Bang Y-J, Van Cutsem E, Feyereislova A etal. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697.
7. Jørgensen J T. Targeted HER2 treatment in advanced gastric cancer. Oncology 2010; 78: 26-33.
8. Moasser M M. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007; 26: 6469-6487.
9. Hicks D G, Whitney-Miller C. HER2 testing in gastric and gastroesophageal junction cancers: a new therapeutic target and diagnostic challenge. Appl Immunohistochem Mol Morphol 2011; 19: 506-508.
10. Lange T, Nentwich M F, Lüth M etal. Trastuzumab has anti-metastatic and anti-angiogenic activity in a spontaneous metastasis xenograft model of esophageal adenocarcinoma. Cancer Lett 2011; 308: 54-61.
11. Beales I L P, Ogunwobi O, Cameron E etal. Activation of Akt is increased in the dysplasia-carcinoma sequence in Barrett's oesophagus and contributes to increased proliferation and inhibition of apoptosis: a histopathological and functional study. BMC Cancer 2007; 7: 97.
12. Fassan M, Ludwig K, Pizzi M etal. Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas. Hum Pathol 2012; 43: 1206-1212.
13. Albarello L, Pecciarini L, Doglioni C. HER2 testing in gastric cancer. Adv Anat Pathol 2011 Jan; 18: 53-59.
14. Park D I, Yun J W, Park J H etal. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006; 51: 1371-1379.
15. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008; 19: 1523-1529.
16. Hofmann M, Stoss O, Shi D etal. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52: 797-805.
17. Barros-Silva J D, Leitão D, Afonso L etal. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer 2009; 100: 487-493.
18. Marx A H, Tharun L, Muth J etal. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 2009; 40: 769-777.
19. Koltz B R, Hicks D G, Whitney-Miller C L. HER2 testing in gastric and esophageal adenocarcinoma: new diagnostic challenges arising from new therapeutic options. Biotech Histochem 2012; 87: 40-45.
20. Villanacci V, Rossi E, Grisanti S etal. Targeted therapy with trastuzumab in dysplasia and adenocarcinoma arising in Barrett's esophagus: a translational approach. Minerva Gastroenterol Dietol 2008; 54: 347-353.
21. Rossi E, Villanacci V, Bassotti G etal. TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma. Histopathology 2010; 57: 81-89.
22. Fassan M, Mastracci L, Grillo F etal. Early HER2 dysregulation in gastric and oesophageal carcinogenesis. Histopathology 2012; 61: 769-776.
23. Goetz M, Wang T D. Molecular imaging in gastrointestinal endoscopy. Gastroenterology 2010; 138: 828-833.e1.
24. Johnson E A, De Lee R, Agni R etal. Probe-based confocal laser endomicroscopy to guide real-time endoscopic therapy in Barrett's esophagus with dysplasia. Case Rep Gastroenterol 2012; 6: 285-292.
25. Goetz M, Kiesslich R. Confocal endomicroscopy: in vivo diagnosis of neoplastic lesions of the gastrointestinal tract. Anticancer Res 2008; 28 (1B): 353-360.
26. Bertani H, Pigò F, Dabizzi E etal. Advances in endoscopic visualization of Barrett's esophagus: the role of confocal laser endomicroscopy. Gastroenterol Res Pract 2012; 2012: 493961.
27. Kiesslich R, Burg J, Vieth M etal. Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo. Gastroenterology 2004; 127: 706-713.
28. Hoetker M S, Kiesslich R, Diken M etal. Molecular in vivo imaging of gastric cancer in a human-murine xenograft model: targeting epidermal growth factor receptor. Gastrointest Endosc 2012; 76: 612-620.
29. Raggi M, Langer R, Feith M etal. Successful evaluation of a new animal model using mice for esophageal adenocarcinoma. Langenbecks Arch Surg 2010; 395: 347-350.
30. Garman K S, Orlando R C, Chen X. Review: experimental models for Barrett's esophagus and esophageal adenocarcinoma. Am J Physiol Gastrointest Liver Physiol 2012; 302: G1231-1243.
31. Ingravallo G, Dall'Olmo L, Segat D etal. CDX2 hox gene product in a rat model of esophageal cancer. J Exp Clin Cancer Res 2009; 28: 108.
32. Oh D S, DeMeester S R, Dunst C M etal. Validation of a rodent model of Barrett's esophagus using quantitative gene expression profiling. Surg Endosc 2009; 23: 1346-1352.
33. Goldstein S R, Yang G Y, Curtis S K etal. Development of esophageal metaplasia and adenocarcinoma in a rat surgical model without the use of a carcinogen. Carcinogenesis 1997; 18: 2265-2270.
34. Kumagai H, Mukaisho K, Sugihara H etal. Cell kinetic study on histogenesis of Barrett's esophagus using rat reflux model. Scand J Gastroenterol 2003; 38: 687-692.
35. Miwa K, Sahara H, Segawa M etal. Reflux of duodenal or gastro-duodenal contents induces esophageal carcinoma in rats. Int J Cancer 1996; 274: 269-274.
36. Dedja A, Dall'Olmo L, Cadrobbi R etal. Heterotopic cardiac xenotransplantation in rodents: report of a refined technique in a hamster-to-rat model. Microsurgery 2005; 25: 227-234.
37. Lu S, Lowe A W, Triadafilopoulos G etal. Endoscopic evaluation of esophago-gastro-jejunostomy in rat model of Barrett's esophagus. Dis Esophagus 2009 Jan; 22: 323-330.
38. Beales I L, Ogunwobi O, Cameron E, El-Amin K, Mutungi G, Wilkinson M. Activation of Akt is increased in the dysplasia-carcinoma sequence in Barrett's oesophagus and contributes to increased proliferation and inhibition of apoptosis: a histopathological and functional study. BMC Cancer 2007; 7: 97.
39. Liu J, Zuo X, Li C etal. In vivo molecular imaging of epidermal growth factor receptor in patients with colorectal neoplasia using confocal laser endomicroscopy. Cancer Lett 2013; 330: 200-207.
40. Langer R, Rauser S, Feith M etal. Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation. Mod Pathol 2011; 24: 908-916.